World News

The divestment positions Halo to focus on expanding into more complex drug-product manufacturing services while strengthening its presence in the sterile CDMO market.

The acquisition encompasses MDCO’s complete portfolio of ophthalmic devices, including intraocular lenses (IOL), implantable contact lenses (Phakic Lens), and various refractive device platforms.

CSPC is expected to receive an additional USD3.5 billion if the programs successfully meet development and regulatory milestones, in addition to royalties from any drugs approved under the partnership.

The trial will enroll up to 105 Japanese men across 11 sites throughout the country, with the collected data intended to support a future marketing authorization submission for TLX591-Px in Japan.

This new facility marks Lilly’s fourth major U.S. manufacturing project in recent years and adds to its broader domestic expansion strategy.

The innovative approach uses lab-grown heart tissue made from reprogrammed adult stem cells, delivered through a tiny incision rather than opening the entire chest cavity.

The World Health Organization has listed Nipah among its top ten priority diseases alongside pathogens like Covid-19 and Zika due to its potential to trigger epidemics.

Kenmare Bio will obtain worldwide development and commercialization rights to an experimental oral small molecule known as FHND5032, with the exception of Greater China, where Chia Tai Feng Hai will retain control.

Eli Lilly will obtain exclusive global rights to advance these programmed recombinases through preclinical studies, clinical development, and eventual commercialization.

The investment will enhance AstraZeneca’s existing manufacturing sites in Wuxi, Beijing, Qingdao, and Taizhou, which already serve patients in China and across 70 international markets.